FMP
TCR2 Therapeutics Inc.
TCRR
NASDAQ
Inactive Equity
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
1.48 USD
0 (0%)
TCRR Financial Statements
Year
2022
2021
2020
2019
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
123.08M
99.74M
68.7M
51.38M
Research and Development
98.64M
77.24M
51.98M
37.49M
Selling, General & Administrative Expenses
24.44M
22.5M
16.72M
13.89M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
24.44M
22.5M
16.72M
13.89M
Other Expenses
30.42M
0
0
0
Operating Income
-153.5M
-99.74M
-68.7M
-51.38M
Total Other Income/Expenses Net
1.94M
224k
1.74M
3.88M
Income Before Tax
-151.56M
-99.52M
-66.96M
-47.5M
Income Tax
261k
289k
161k
102k
Net Income
-151.82M
-99.81M
-67.12M
-47.6M
Basic EPS
-3.93
-2.63
-2.4
-2.26
EPS Diluted
-3.93
-2.63
-2.4
-2.26
Basic Average Shares
38.63M
37.94M
27.99M
21.1M
Diluted Average Shares
38.63M
37.94M
27.99M
21.1M
EBITDA
-89.62M
-96.92M
-67.11M
-50.52M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-349.52M
-249.72M
-182.59M
-85.59M
Net Income
-151.82M
-99.81M
-67.12M
-47.6M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-501.34M
-349.52M
-249.72M
-182.59M
Other Distributions
-151.82M
-99.81M
-67.12M
-97M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
28.68M
45.36M
10.01M
4.93M
Annual Depreciation
63.88M
2.83M
1.59M
862k
Capital Expenditure
-15.45M
-11.45M
-7.16M
-3.88M
Net PPE
-19.75M
53.98M
15.59M
7.94M
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
